Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis

[1]  P. Schauer,et al.  Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[2]  C. Stier,et al.  Are We Missing Treatment Standards for Thromboprophylaxis of the Obese and Super-Obese Patient Population? A Prospective Systematic Cohort Study , 2020, Obesity Surgery.

[3]  Jennifer F. Hughes,et al.  Conservation, acquisition, and functional impact of sex-biased gene expression in mammals , 2019, Science.

[4]  K. Deshpande,et al.  Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[5]  Mary R. Kwaan,et al.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. , 2018, The Cochrane database of systematic reviews.

[6]  O. Mann,et al.  Perioperative Short-Term Outcome in Super-Super-Obese Patients Undergoing Bariatric Surgery , 2018, Obesity Surgery.

[7]  C. Schulman,et al.  Association of Anti–Factor Xa–Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma , 2017, JAMA surgery.

[8]  G. Lahat,et al.  Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[9]  P. Ball,et al.  Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. , 2017, Critical reviews in oncology/hematology.

[10]  M. Vix,et al.  Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[11]  Matthew Wei,et al.  The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis , 2015, Hematology reports.

[12]  A. Huitema,et al.  Fixed-Dose Enoxaparin After Bariatric Surgery: The Influence of Body Weight on Peak Anti-Xa Levels , 2015, Obesity Surgery.

[13]  S. le Cessie,et al.  Sex Difference in Risk of Second but Not of First Venous Thrombosis: Paradox Explained , 2014, Circulation.

[14]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[15]  I. Martinelli,et al.  Risk factors for venous and arterial thrombosis. , 2011, Blood transfusion = Trasfusione del sangue.

[16]  Thomas Meitinger,et al.  Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution , 2010, Nature Genetics.

[17]  W. Lim.  Using low molecular weight heparin in special patient populations , 2010, Journal of Thrombosis and Thrombolysis.

[18]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[19]  Alberto Zanardi,et al.  Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). , 2009, Thrombosis research.

[20]  E. Nutescu,et al.  Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings , 2009 .

[21]  D. Chang,et al.  Postoperative Venous Thromboembolism Rates Vary Significantly After Different Types of Major Abdominal Operations , 2008, Journal of Gastrointestinal Surgery.

[22]  A. Lopes,et al.  Risk of Venous Thromboembolism and Efficacy of Thromboprophylaxis in Hospitalized Obese Medical Patients and in Obese Patients Undergoing Bariatric Surgery , 2006, Obesity surgery.

[23]  S. Schulman,et al.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.

[24]  M. Schwartz,et al.  Heparin Thromboprophylaxis in Gastric Bypass Surgery , 2003, Obesity surgery.

[25]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[26]  I Iturralde,et al.  Deep vein thrombosis and pulmonary embolism , 1990 .

[27]  F. Franconi,et al.  Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics. , 2017, Current medicinal chemistry.

[28]  D. Hoppensteadt,et al.  Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin , 2003, Clinical pharmacokinetics.